Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

Updates Expected Ahead Of Phase III Head And Neck Results

 
• By Mandy Jackson
  
Nanobiotix also plans to execute deals around a second nanoparticle platform (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D